{"entity":{"id":"ctnna2","kind":"target","name":"CTNNA2","aka":["catenin alpha 2","Catenin alpha-2","CAP-R","CT114"],"tldr":"CTNNA2 (Catenin alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Hepatocellular carcinoma, Head and neck squamous cell carcinoma and 4 more.","summary":"May function as a linker between cadherin adhesion receptors and the cytoskeleton to regulate cell-cell adhesion and differentiation in the nervous system. Required for proper regulation of cortical neuronal migration and neurite growth. It acts as a negative regulator of Arp2/3 complex activity and Arp2/3-mediated actin polymerisation.\n\nIntOGen calls it a driver in 12 cohorts (9 activating, 2 loss-of-function), covering Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Lung Adenocarcinoma, Melanoma, Pancreatic Adenocarcinoma and others.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:2510","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2510"},{"label":"UniProt P26232","url":"https://www.uniprot.org/uniprotkb/P26232/entry"},{"label":"NCBI Gene 1496","url":"https://www.ncbi.nlm.nih.gov/gene/1496"},{"label":"Ensembl ENSG00000066032","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000066032"}],"tags":["cancer-genes-wave"],"related":["intogen"],"cancers":["prostate","hcc","head-and-neck","pancreatic","cholangiocarcinoma","nsclc","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 9 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier \"cohort-driver\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CTNNA2","role":["oncogene-driver","tumour-suppressor"],"evidenceTier":"cohort-driver","sources":[{"label":"HGNC HGNC:2510","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2510","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P26232","url":"https://www.uniprot.org/uniprotkb/P26232/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"IntOGen CTNNA2","url":"https://www.intogen.org/search?gene=CTNNA2","note":"driver in 12 cohorts (Act 9, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:2510","ensembl":"ENSG00000066032","uniprot":"P26232","entrez":"1496","biology":"May function as a linker between cadherin adhesion receptors and the cytoskeleton to regulate cell-cell adhesion and differentiation in the nervous system. Required for proper regulation of cortical neuronal migration and neurite growth. It acts as a negative regulator of Arp2/3 complex activity and Arp2/3-mediated actin polymerisation. It thereby suppresses excessive actin branching which would impair neurite growth and stability. Regulates morphological plasticity of synapses and cerebellar and hippocampal lamination during development. Functions in the control of startle modulation. Location: Cell membrane; Cytoplasm; Cytoplasm, cytoskeleton; Cell junction, adherens junction (UniProt). Locus 2p12 (HGNC).","whereFound":["Prostate cancer: IntOGen driver in 4 cohorts (PRAD)","Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)","Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)","Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)","Biliary tract cancer: IntOGen driver in 2 cohorts (CHOL)","Non-small-cell lung cancer: IntOGen driver in 2 cohorts (LUAD)"],"targetClass":"oncogene","prevalence":[]},"route":"/targets/ctnna2/","neighbours":{"collection":[{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"}],"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}